Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
9.64
-0.23 (-2.33%)
At close: Jul 15, 2026, 4:00 PM EDT
9.51
-0.13 (-1.35%)
After-hours: Jul 15, 2026, 7:38 PM EDT
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
706.33M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 400.05M |
| Gyre Therapeutics | 117.05M |
| REGENXBIO | 87.82M |
| Omeros | 9.89M |
| Prime Medicine | 4.03M |
| Allogene Therapeutics | 22.00K |
CADL News
- 2 days ago - Candel Therapeutics initiated with a Buy at Stifel - TheFly
- 7 days ago - Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Candel Therapeutics Slides: Corporate presentation - Filings
- 14 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - GlobeNewsWire
- 20 days ago - Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer - GlobeNewsWire
- 22 days ago - Candel Therapeutics Transcript: AGM 2026 - Transcripts
- 6 weeks ago - Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts